Find Resources
Promising Practices that show evidence of effectiveness in improving public health outcomes in a specific real-life setting, as indicated by achievement of aims consistent with the objectives of the activities, and are suitable for adaptation by other communities.
RELEASE DATE:
Peer Review Study
Community health workers, sometimes called health navigators, played a key role in the public health response to COVID-19, especially among communities of color. This report describes how the community health workforce can be developed by public health departments and shares findings from a community health worker training program focused on vaccination, prevention, and contact tracing.
Promising Practices that show evidence of effectiveness in improving public health outcomes in a specific real-life setting, as indicated by achievement of aims consistent with the objectives of the activities, and are suitable for adaptation by other communities.
RELEASE DATE:
Peer Review Study, Summary Report/Recommendations
Article outlines how an opioid treatment program in the Bronx, NY adjusted their clinical practice with COVID-19 and their recommendations for treatment programs going forward. Balancing Covid-19 safety and the need to safely administer medications for opioid use disorder, this program ultimately made changes that allowed for more patient-driven treatment plans that enable fewer in person clinic visits. The article advocates for patient-centered care that encourages people to safely self-manage medication, focusing on patient-centered measures in clinical decision-making, and making appropriate changes to payment/insurance models that allow for such patient-centered care.
Promising Practices that show evidence of effectiveness in improving public health outcomes in a specific real-life setting, as indicated by achievement of aims consistent with the objectives of the activities, and are suitable for adaptation by other communities.
RELEASE DATE:
Peer Review Study
This article conducts a retrospective case-control study of electronic health records of individuals who were diagnosed with COVID-19 and have a recent diagnosis of substance use disorder (SUD). The results show that those diagnosed with SUD, particularly African Americans and those with opioid use disorder (OUD), are more likely to contract COVID-19, as well as suffer worsening outcomes such as hospitalization and mortality due to COVID-19. This article shows that an increase in SUD screening could be a factor in mitigating the spread of COVID-19 in this community.
Emerging Practices that show potential to achieve desirable public health outcomes in a specific real-life setting and produce early results that are consistent with the objectives of the activities and thus indicate effectiveness.
RELEASE DATE:
Peer Review Study
This study describes harm reduction and health services provided by the U.S. syringe services programs (SSPs) in 2019 and changes in provision of those services in 2020. Many SSPs that offered health services in 2019 and remained operational in 2020 increased telehealth provision of mental health and primary care services, increased MOUD provision, and expanded harm reduction services, but most SSPs reduced or stopped on-site HIV and HCV testing. With the record high opioid overdose fatality rates in 2020, sustaining the trajectory of SSP growth and innovation leading up to and through 2020 requires ensuring adequate and flexible funding to support the life-saving work of SSPs in preventing future overdose deaths and outbreaks of HIV and HCV.
Promising Practices that show evidence of effectiveness in improving public health outcomes in a specific real-life setting, as indicated by achievement of aims consistent with the objectives of the activities, and are suitable for adaptation by other communities.
RELEASE DATE:
Peer Review Study
This article describes the implementation of a medical student-run, free virtual clinic providing medication assisted treatment (MAT) for opioid use disorder (OUD) in Miami, Florida during the COVID-19 pandemic. Eligibility criteria for accessing services through the clinic included Florida residency and an income below 200% of the federal poverty level. The article describes how the students promoted the clinic, the process for providing MAT virtually (under supervision of an attending physician), patient characteristics, and reports process evaluation data for the clinic. The practice strategy this article is focused on is access to MAT for people with OUD during the COVID-19 pandemic.
Promising Practices that show evidence of effectiveness in improving public health outcomes in a specific real-life setting, as indicated by achievement of aims consistent with the objectives of the activities, and are suitable for adaptation by other communities.
RELEASE DATE:
Peer Review Study
This article presents results from an intervention to provide medication assisted treatment (MAT) to individuals with opioid use disorder via telemedicine. This article describes outcomes for patients enrolled in the NYC Health+Hospitals Virtual Buprenorphine Clinic during the first nine weeks of the COVID-19 pandemic (March 26, 2020 through May 28, 2020). Results from this evaluation were mixed. Loss-to-follow-up was similar to rates observed in studies of in-person opioid treatment, but the authors note telemedicine-based opioid treatment poses barriers to patients who frequently change mobile phones or phone numbers, and patients with unreliable internet access. The authors also note that the generalizability of this intervention may be limited in settings with different patient populations or staff capacity.
Emerging Practices that show potential to achieve desirable public health outcomes in a specific real-life setting and produce early results that are consistent with the objectives of the activities and thus indicate effectiveness.
RELEASE DATE:
Peer Review Study
This article evaluates a partnership between the University of Maryland, Baltimore – an urban academic treatment center – and multiple rural behavioral health treatment centers to provide medication assisted treatment (MAT) to individuals with opioid use disorder via videoconference. Retention rates and toxicology results for patients who received MAT via videoconference were comparable to those receiving face-to-face treatment. It should be noted that data for this study were collected prior to the onset of the COVID-19 pandemic.
Emerging Practices that show potential to achieve desirable public health outcomes in a specific real-life setting and produce early results that are consistent with the objectives of the activities and thus indicate effectiveness.
RELEASE DATE:
Peer Review Study
This article presents the results of a non-randomized cohort study comparing opioid agonist therapy (medication assisted treatment [MAT]) for opioid use disorder received via telemedicine, in-person, or a mix of telemedicine and in-person visits. The study was conducted between January 2011 and June 2012 in Ontario, Canada. The telemedicine group had the highest one-year treatment retention rate, followed by the mixed group, and the in-person group had the lowest one-year treatment retention rate. The results suggest telemedicine could be an effective means of increasing access to MAT for opioid use disorder. It should be noted that the study was conducted prior to the COVID-19 pandemic, and replicability will vary based on local resources and MAT regulations.
Novel Practices that show potential to achieve desirable public health outcomes in a specific real-life setting and are in the process of generating evidence of effectiveness or may not yet be tested.
RELEASE DATE:
Peer Review Study
Based on a literature review, the article synthesizes strategies used to prevent interruption of care for persons with opioid use disorders (SUDs). The review included OUD treatment and harm reduction services in five continents and a range of settings from substance use treatment to street outreach programs. Innovative service modifications to adapt to COVID-19 circumstances primarily involved expanded use of telehealth services (e.g., telemedicine visits for buprenorphine, virtual individual or group therapy sessions, provision of donated or publicly available phones), increased take-home medication allowances for methadone and buprenorphine, expanded uptake of long-acting opioid medications (e.g. extended-release buprenorphine and naltrexone), home delivery of services (e.g. MOUD, naloxone and urine drug screening), outreach and makeshift services for delivering MOUD and naloxone, and provision of a safe supply of opioids.
Emerging Practices that show potential to achieve desirable public health outcomes in a specific real-life setting and produce early results that are consistent with the objectives of the activities and thus indicate effectiveness.
RELEASE DATE:
Peer Review Study
This article presents the results of a non-randomized controlled trial comparing in-person vs. telemedicine treatment for pregnant women with opioid use disorder in South Carolina. The authors found no statistically significant difference in treatment outcomes for women who received care in-person vs. via telemedicine, and no statistically significant difference in outcomes for the newborns of women in these respective groups. The authors were unable to assign trial participants to telemedicine vs. in-person care at random due to the inability of some rural patients to attend treatment in person. Also, the sample size was not sufficient to achieve ~80% power to detect a difference between the two groups. At the same time, the practice strategy is considered useful for helping to deliver telehealth treatment for vulnerable populations, including pregnant and newly parenting people with substance use disorder, and people living in rural communities.